Avadel Pharmaceuticals Stock News

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in participate in a virtual fireside chat at the Oppenheimer 32 nd Annual Healthcare Conference on Thursday, March 17 at 10:40 a.m. ET.

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Ex

Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s traded shares stood at 0.36 million during the last session, with the company’s beta value hitting 1.02. At the close of trading, the stock’s price was $7.49, to imply a decrease of -1.71% or -$0.13 in intraday trading. The AVDL share’s 52-week high remains $11.59, putting it -54.74% down since that … Avadel Pharmaceuticals plc (NASDAQ: AVDL) Has Succeeded To Excite In 2022, The Stock Is Down -7.30% Year-To-Date Read More »

DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Dougl

DUBLIN, Ireland , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Douglas Williamson , MBChB, as Chief Medical Officer. “Doug is an outstanding addition to the Avadel

DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief E

DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 at 1:40 p.m. ET.

DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Exe

During the last session, Avadel Pharmaceuticals plc (NASDAQ:AVDL)s traded shares were 0.66 million, with the beta value of the company hitting 1.11. At the end of the trading day, the stocks price was $7.52, reflecting an intraday loss of -3.47% or -$0.27. The 52-week high for the AVDL share is $11.59, that puts it down A Bull Market Continues To Unfold On Avadel Pharmaceuticals plc (NASDAQ: AVDL), As It Continued To Rise 12.57% In Year-To-Date Read More »

Goldman Sachs Group Inc. boosted its stake in Avadel Pharmaceuticals plc (NASDAQ:AVDL) by 73.8% in the second quarter, HoldingsChannel reports. The firm owned 34,515 shares of the companys stock after buying an additional 14,661 shares during the period. Goldman Sachs Group Inc.s holdings in Avadel Pharmaceuticals were worth $232,000 as of its most recent SEC []

Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.

Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) concluded the trading at $8.14 on Friday, December 03 with a fall of -4.46% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $8.52 and 5Y monthly beta was reading 1.17 with its price kept floating in the Avadel Pharmaceuticals plc (AVDL) Should Be Considered Now, Despite A Loss Of -29.77% From High Read More »

Squarepoint Ops LLC lifted its stake in Avadel Pharmaceuticals plc (NASDAQ:AVDL) by 135.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 28,162 shares of the companys stock after purchasing an additional 16,194 shares during the quarter. Squarepoint Ops LLCs holdings in Avadel Pharmaceuticals []